



04-08-

Express Mail No.: EL 477 035 293

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Vournakis *et al.*

Serial No.: 09/781,182

Group Art Unit: 1614

Filed: February 12, 2001

Examiner: To Be Assigned

For: COMPOSITIONS AND METHODS FOR Attorney Docket No.: 7867-022-999  
MODULATION OF VASCULAR  
STRUCTURE AND/OR FUNCTION

## PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.115

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the Rule 115 of the Rules of Practice, please enter the following amendments and consider the following remarks. Applicants submit herewith: (1) Exhibit A, a marked up version of the amended paragraph of the specification (2) Exhibit B, a marked up version of the amended claims; (3) Exhibit C, a copy of the claims as they will be pending upon entry of the Preliminary Amendment; (3) an Amendment Fee Transmittal Sheet; (5) an Information Disclosure Statement; and (6) a List of References Cited listing references AA to CH together with a copy of references AA - CH.

## IN THE SPECIFICATION:

A marked up version of the following amended paragraph is attached hereto as Appendix A. Matter that has been deleted from the paragraph is indicated by brackets and matter that has been added to the paragraph is indicated by underlining:

Please amend the specification as follows:

On page 72, please replace the paragraph beginning "The procedure was repeated with U-46619" with the following paragraph:

The procedure was repeated with U-46619 followed by p-GlcNAc. p-GlcNAc produced a concentration-dependent vasocontraction from 14 to 140  $\mu\text{g/ml}$ , as indicated in Figure 22. At a developed concentration of 140  $\mu\text{g/ml}$ , p-GlcNAc significantly contracted

RECEIVED  
APR 10 2002  
TECH CENTER 1600/2900  
G#1614  
4-15-02

28118760 051101 41000000 110011 2002/05/10

01 FC:203 10  
02 FC:202

NY2 - 1279714.3